Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Lifestyle Health and Longevity

4 in 5 Americans Say Healthcare Costs Are the Nation’s Top Health Problem — and Nobody Agrees on Who Should Fix It

by Team Lumida
August 18, 2026
in Health and Longevity
Reading Time: 4 mins read
A A
0
doctor holding red stethoscope

Photo by Online Marketing on Unsplash

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp
  • Nearly 4 in 5 U.S. adults — across all political affiliations, income levels, and insurance types — identified high health insurance premiums or out-of-pocket costs as the most important healthcare problem facing the country, according to a Commonwealth Fund survey of 25,873 adults conducted May 4-26, making affordability the rare issue that unites an otherwise deeply divided electorate.
  • The affordability crisis has a concrete trigger: after enhanced federal subsidies for Affordable Care Act marketplace plans expired, average out-of-pocket premiums for ACA plans surged 58% in 2026, pricing out millions of previously subsidized enrollees and exposing the degree to which the prior enrollment surge was subsidy-driven rather than a structural improvement in coverage affordability.
  • Despite bipartisan agreement on the problem, Americans are sharply split on the solution: 65% of Democrats say the federal government should be primarily responsible for reducing healthcare costs, compared to just 36% of Republicans — who are instead more likely (40% vs. 19% of Democrats) to place responsibility on insurance companies, reflecting a fundamental ideological divide about the role of government in healthcare markets.
  • The employer-sponsored coverage market — which covers roughly 160 million Americans — is also poised to shift more costs onto workers: 48% of large employers told Mercer they expect to make plan design changes next year that increase employees’ out-of-pocket spending, signaling that the affordability pressure is not confined to individual and marketplace coverage but is spreading across the entire insurance system.

What Happened?

The Commonwealth Fund released survey data from 25,873 U.S. adults showing that high premiums and out-of-pocket healthcare costs have become the defining concern of Americans’ relationship with the healthcare system. The concern is not segmented by politics: 45% of Republicans, 44% of Democrats, and 42% of independents named premiums or out-of-pocket costs as the most important healthcare problem — a rare instance of genuine bipartisan convergence on a major domestic issue. The survey comes against a backdrop of sharply rising costs: ACA marketplace premiums jumped 58% in 2026 after the enhanced subsidies that had artificially suppressed enrollee costs expired, reversing years of subsidy-driven enrollment gains and exposing millions of Americans to the full market-rate cost of individual coverage for the first time.

Why It Matters?

The survey crystallizes a fundamental tension in U.S. healthcare: costs are rising across every coverage type simultaneously, and neither the political system nor the market appears positioned to address the root causes at scale. The expiration of ACA subsidies was a policy choice — one that immediately translated into a 58% premium increase for marketplace enrollees, demonstrating the extent to which the prior coverage gains were financially fragile. Meanwhile, large employers — historically the most stable insurance market — are planning to pass more costs to workers, suggesting the affordability erosion is systemic rather than isolated to the individual market. The partisan split on solutions is equally significant: with Democrats favoring federal intervention and Republicans preferring insurer accountability, there is no obvious legislative path to cost relief in the current political environment. That deadlock means the cost trajectory is likely to continue absent a structural market disruption or a significant shift in the political balance of power.

What’s Next?

The 2026 midterm environment will be shaped in part by healthcare cost anxiety — the survey data suggests this is one of the few issues where voter frustration cuts across party lines. The key policy questions heading into the next legislative cycle include whether Congress will restore any version of the ACA enhanced subsidies (which would require bipartisan cooperation that currently appears unlikely), whether state-level action can fill the gap, and whether the employer-sponsored market’s cost-shifting trend will accelerate enough to push additional millions into the individual and marketplace coverage pools. On the insurer side, pressure is building for companies like UnitedHealth, CVS Health, and Cigna to demonstrate moderation in premium growth or prior authorization practices — though the financial incentives for restraint remain limited in a concentrated market. For workers, the near-term outlook is further out-of-pocket exposure as employers execute the plan design changes flagged in the Mercer survey.

Source: Healthcare Dive

Previous Post

AI Is Driving Up Treasury Yields: The $1.5 Trillion Corporate Bond Binge Is Crowding Out the U.S. Government

Next Post

US Home Values Hit $371,774 in July as Properties Sit Five Days Longer Before Going Pending

Recommended For You

Wealthy, Healthy, and Ready to Spend: Baby Boomers Are Driving a Global Travel Boom the Industry Is Racing to Serve

by Team Lumida
23 hours ago
couple kissing on the road during daytime

Baby boomers — flush with retirement savings and in better health than previous generations — are fueling a high-end travel surge, with the industry responding with private-plane tours,...

Read more

385 Million Patient Records Breached and Counting — DentaQuest’s 15M-Person Hack Leads a New Wave of Healthcare Cybersecurity Disasters

by Team Lumida
6 days ago
person sitting while using laptop computer and green stethoscope near

The updated Healthcare Dive breach tracker reveals a sector in crisis: DentaQuest's 15M breach in 2026, Conduent's 62M in 2025, and Change Healthcare's record 192.7M in 2024.

Read more

Healthcare Stocks Are Now an Implicit AI Short — Semiconductors and Pharma Have Flipped to Negative Correlation

by Team Lumida
7 days ago
turned on monitoring screen

A structural shift is underway in equity markets: the VanEck Semiconductor ETF and the State Street Health Care ETF have moved into negative correlation, meaning healthcare has effectively...

Read more

Patients Are Using AI to Interpret Their Medical Test Results Before Seeing Doctors — And Doctors Are Struggling to Untangle the Errors

by Team Lumida
2 weeks ago
doctor holding red stethoscope

Roughly a third of American adults now consult AI for health advice, and the majority view test results online before speaking with a doctor — a trend accelerated...

Read more

Novo Nordisk’s $10 Billion Cardiovascular Bet Fails — Ziltivekimab Misses Heart Attack and Stroke Endpoint, Stock Drops 10.5%

by Team Lumida
3 weeks ago
Novo Nordisk Q2 2024 Earnings Highlights

Novo Nordisk's experimental drug ziltivekimab — a monthly IL-6 inhibitor injection targeting cardiovascular disease, chronic kidney disease, and inflammation in a market Jefferies estimates at $10B+ annually —...

Read more

Trump Administration to End $3.6 Billion Medicare Drug Premium Subsidy — Seniors Face Higher Part D Costs in 2027

by Team Lumida
3 weeks ago
Supreme Court Signals It Will Strike Down Trump’s Birthright Citizenship Order

The Trump administration will not renew the Part D Low Income Premium Subsidy program after 2026, eliminating $3.6 billion in annual payments to insurers that have been holding...

Read more

80% of People Are Deficient in Essential Vitamins — Here Are the 10 You Actually Need and Where to Get Them

by Team Lumida
3 weeks ago
oranges, peas, and limes on a wooden table

Most people are not getting enough of the 13 essential vitamins their bodies require — here is a practical guide to the most critical nutrients, what they do,...

Read more

Whoop Enters Clinical Care With Joint Replacement Recovery Pilot — Can Wearable Biometrics Reduce Opioids and Speed Recovery?

by Team Lumida
4 weeks ago
a close up of a human skull on a black background

Whoop and surgical software company Kinomatic have launched a 12-week pilot program called Restore across three California orthopedic clinics to test whether continuous biometric monitoring — heart rate...

Read more

$399 Signal Ring Claims to Replace the Blood Pressure Cuff — No Calibration, No Subscription, Clinical Trial at Stanford

by Team Lumida
1 month ago
Fingers hold a black smart ring with circuits visible.

Vital Signals, a three-year-old startup, has launched a $399 Signal Ring that claims to track blood pressure as accurately as a traditional arm cuff — without requiring any...

Read more

Novo’s Obesity Pill Commands 89% Market Share — Lilly’s Foundayo Captures Just 11% After Three Months on Market

by Team Lumida
1 month ago
Novo’s Obesity Pill Commands 89% Market Share — Lilly’s Foundayo Captures Just 11% After Three Months on Market

Novo Nordisk's Wegovy pill has seized 89% of new oral obesity pill prescriptions since its January 2026 launch, leaving Eli Lilly's Foundayo — launched in April — with...

Read more
Next Post
a view of a city from the top of a building

US Home Values Hit $371,774 in July as Properties Sit Five Days Longer Before Going Pending

Ken Griffin Warns Trump-Era Political вмешening Is Distorting Corporate Decision-Making

Citadel Securities: Spiking Bond Yields Reflect Fed Policy Risk — and AI Investment Case Is Shifting to Cloud, Away From Frontier Models

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

Caterpillar’s AI Power Play: Generators, Not Excavators, Are Driving the Stock

Caterpillar’s AI Power Play: Generators, Not Excavators, Are Driving the Stock

December 31, 2025
Citizens Financial Group Q4 2024 Earnings Analysis

Citizens Financial Group Q4 2024 Earnings Analysis

January 18, 2025
tall trees in front of high-rise buildings

How Wall Street’s Real Estate Bets Crumbled: Investors’ Nightmares Unfold

June 7, 2024

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto data centers Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Intel Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018